ROSETEMIB S.K. is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as an adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in colour, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
**Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
*** Disclaimer
The information provided herein is not intended as medical advice and must not be relied upon for diagnosis, treatment, or the provision of medical care. It does not replace the official prescribing/patient leaflet or consultation with a qualified healthcare professional. Before any use, always review the official physician/patient leaflet and consult a licensed physician. The company assumes no responsibility or liability for any reliance placed on the information presented on this page.
